Abstract
This study was conducted to determine whether short-term administration of transforming growth factor (TGF)-β would be as effective for inducing chondrogenesis in human mesenchymal stem cells (hMSCs) as continuous treatment. Four groups of hMSCs were cultured in a monolayer for 3 days followed by a pellet culture for 3 weeks under various conditions: group A, the control group, no growth factors treated; group B, 5 ng/ml of TGF-β<sub>2</sub> was treated for 3 days in monolayer culture; group C, 5 ng/ml of TGF-β<sub>2</sub> was treated for 3 days in a monolayer culture and the initial 3 days of pellet culture; group D, 5 ng/ml of TGF-β<sub>2</sub> was treated for 3 days in a monolayer culture and the initial 10 days of pellet culture; group E, 5 ng/ml of TGF-β<sub>2</sub> was continuously treated throughout the culture period. Glycosaminoglycan contents significantly increased in group E only. Real-time PCR indicated that expression of Sox-9, type II collagen, type II procollagen B and type X collagen increased with longer duration of TGF-β<sub>2</sub> treatment. The histological findings showed that longer duration of TGF-β<sub>2</sub> treatment led to significantly better quality of chondrogenesis. This study demonstrated that longer duration of TGF-β treatment is necessary for effective chondrogenesis in hMSCs from bone marrow.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
